ArticleFood science & nutrition2026
Mitigating Dexamethasone-Induced Muscle Wasting and Mitochondrial Impairment in Mice on a High-Fat and High-Sucrose Diet With Peanut Sprout Extract.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitigating Dexamethasone-Induced Muscle Wasting and Mitochondrial Impairment in Mice on a High-Fat and High-Sucrose Diet With Peanut Sprout Extract.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolonged high-fat and high-sucrose diets (HFHS) diet accelerates skeletal muscle atrophy and impairs muscle function. Combined HFHS diet and dexamethasone (Dex), a synthetic glucocorticoid which involves the induction of protein degradation, will promote atrophy of skeletal muscle. Although we previously demonstrated that peanut sprout extract (PSE) inhibits adipogenesis, its impact on HFHS+Dex-induced muscle atrophy remained unknown. To investigate, we treated C57BL/6 male mice with a control or HFHS diet, with or without PSE (10 mg/kg BW), over 10 weeks, introducing Dex (10 mg/kg BW) once daily for six consecutive days to induce muscle atrophy. PSE treatment reduced skeletal muscle triglyceride accumulation, restored muscle strength (grip and hanging capacity), and mitigated muscle atrophy expression. While systemic interleukin (IL)-1β levels were unaffected, PSE reduced inflammatory gene expression and inhibited nuclear factor-κB (NF-κB) protein expression in skeletal muscle, enhanced mitochondrial function (increased mitochondrial transcription factor A (TFAM), oxidative phosphorylation (OXPHOS) complex IV/V protein expression, but no differences in peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α)). Consistent with these results, PSE protected against muscle atrophy in Dex-treated C2C12 cells by modulating atrophic and inflammatory expression. This study highlights PSE's efficacy in attenuating skeletal muscle atrophy and mitigating inflammation with partial enhancement of mitochondrial function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.